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ABSTRACT

As populations continue to age, their need for medical care continues to rise. This is seen
by the large need for implanted vascular devices (IVADs). IVADs are essential for
individuals with poor venous access and patients requiring long-term venous delivered
drugs. This document will explore the existing IVADs, where they fall short, and where
our device, the IrisPort system, works to solve the unmet needs of patients. The IrisPort
system is a needle-less port system that allows for repeated venous access without the use
of a non-coring needle. Prior art searches have shown that the IrisPort is a novel solution
as it does not require a needle for access. The IrisPort system will follow the FDA
regulatory pathways, by citing several predicate devices, and will be considered a Class II
device. Following these necessary validation steps, the IrisPort will provide patients with
a better quality of life due to its smaller dimensions and needless nature, whilst meeting
necessary flowrate, pressure, and radiological requirements.
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INTRODUCTION
Numerous diseases and disorders require repeated venous access for diagnostic testing
and drug administration.1–3 Implanted vascular access devices (IVADs) has been the one
device to revolutionize the world of long-term venous access. They were first used in
1982 and have significantly increased the quality of life of numerous individuals.4,5
IVADs are widely used for patients with poor peripheral venous access and patients who
need long-term vascular access, such as but not limited to patients receiving
chemotherapy, antibiotics, total parenteral nutrition, or frequent blood samples.4 While
the ease of these procedures has increased greatly, there is still a large portion of patients
that have “needle-phobia” and “procedure-phobia”. Both phobias lead to lower overall
patient compliance.3 “Needle-phobia” and “procedure-phobia” is especially prevalent in
children.3 Where patients can be as young as 4 months old for IVADs to be implanted.6
The majority of all children, 20-50% of adolescents, and 20-30% of adults indicated a
large fear of needles.3 IVADs are used frequently in cancer patients for the delivery of
intravenous chemotherapy, in which 1.7 million people are diagnosed with cancer each
year within the United States, and 17 million people globally. 7,8 The global estimate is
projected to increase to 26 million by 2040, creating a larger need for chemotherapy in
the near future.8 Nearly half of cancer patients receive chemotherapy during their course
of treatment and the majority of all patients have fear of needles (up to 87%).3
Chemotherapy can be used in conjunction with radiation, surgical removal of tumors,
etc.9
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Traditional intravenous infusion consists of repeated skin puncture, which can be
damaging to veins and surrounding tissue over time. A catheter can be used for these
applications as well, however, IVADs provide several advantages, including improved
body image and minimizing maintenance while not in use, improved mobility, and lower
infection rates.5
Figure 1: Catheter vs IVAD10

B

A

Figure 1-A: Catheter implanted with connection to subclavian vein. Entry site is the point that the catheter
is inserted into the skin. Figure 1-B: An IVAD placed subcutaneously with catheter extending into the
subclavian vein like the catheter. Port is accessed with a huber needle.

The catheters can be either tunneled (implanted subcutaneously) or non-tunneled (not
subcutaneously implanted with entry site). Non-tunneled catheters have higher rates of
infections when compared to both IVADs and tunneled catheters.4 Non-tunneled
catheters have a decreased distance between the skin and the bloodstream when
compared to IVADs and tunneled catheters. This decreased distance makes it more likely
for pathogens to enter the bloodstream. Additionally, non-tunneled catheter tip placement
in the vena cava often results in insufficient blood flow rate.11
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Figure 2: Tunneled vs Non-tunneled12

Implantation under the skin is a distinct characteristic of IVADs. Benefits of a concealed
venous access device include permanent insertion, improved body image of the patient,
and reduced physical limitations.13 IVADs include a reservoir connected to a large vein
through a catheter and are accessed by Huber needles. Huber needles are non-coring
needles specially designed to access implanted vascular devices. Non-coring needles
have a 45º angle at the end of the needle which prevents “coring,” or the removal of
silicon from the implant.
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Figure 3: Non-coring vs Standard Needle14

Huber needles can vary in shape, length, diameter, mechanism of protection against the
blood and bevel design. Upon insertion of an IVAD, the correct size and length of a
Huber needle must be assessed based on the location of the port septum and the patient’s
body type.
Figure 4: Huber Needle Accessing IVAD15

Huber needle is inserted at a 90° angle into the septum to access the reservoir to deliver medication or take
blood samples.
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The smallest size needle appropriate for the patient must be used. If the needle length is
too long, then the needle or port may be damaged upon insertion. If the needle length is
too short, the needle may not pierce the septum. Sterile gauze squares should be placed
under the wings of the port to support the access needle at a 90º angle if the access needle
is not already in perfect position. Using sterile gauze squares to fix imperfect needle
sizing has been a common practice for years. Gauze is an inexpensive material and serves
as a cushion between the skin and the wings of the port. However, this practice should be
reevaluated for the patient’s comfort and safety. Using gauze to support a 90º angle may
not ensure permanent stability for the duration of the needle’s use. Additionally, patient
injury such as a piercing of the septum may occur if the gauze is not properly applied.
In addition, to the delivery of treatments, IVADs allow for blood samples to be taken
easily. When the Huber needle pierces the septa, it creates negative pressure and allows
for an influx of blood. However, it was not until 2017 that an IVAD was made
specifically for apheresis.4 Apheresis is the removal of blood plasma from the body and
its separation into plasma and cells and reintroducing the cells back into the body. This
can be used for patients being treated for autoimmune diseases, in which antibodies are
removed from the blood.
While IVADs have significantly increased the quality of life of patients, there has been
little change to the overall design since its conception. All IVADs have a septa, reservoir,
and catheter. However, sizing issues with Huber needles can lead to a number of
complications (seen in Tables 1-3), including damage to the IVAD requiring surgery to
replace the damaged IVAD. The device described in this document seeks to eliminate the
need of non-coring needles all together and use a needle-less port system, the IrisPort
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System, to deliver the same quality of long-term venous access, with reducing the
number of complications caused by improper Huber needle sizing.
Table 1: Complications Related to IVAD Insertion16
Complication

Symptoms

Etiology

Air embolism

Intrathoracic pressure becomes
less than atmospheric pressure at
the open needle or catheter
Cardiac compression of fluid
accumulation within pericardial
sac due to perforation

Catheter migration

Cardiac arrest, chest pain,
hypotension, breathing
difficulties, tachypnea
Anxiety, chest discomfort,
cyanosis, face and neck
distention, hypotension,
tachycardia, tachypnea
Hypotension, internal or
external bleeding, hematoma,
stroke
Pain, palpitations, occlusion

Chylothorax, Hemothorax,
Hydrothorax, Pneumothorax

Pain, cyanosis, dyspnea,
tachypnea

Bleeding/hematoma

Persistent bleeding,
discoloration

Cardiac Tamponade

Carotid artery puncture

Carotid artery punctured during
percutaneous insertion into
internal jugular vein
Catheter tip no longer located in
superior vena cava
Caused by air, blood, lymph, or
fluid infusion into pleural cavity
due to injury during insertion
Catheter insertion is traumatic or
if inducer sheath is left in place

Table 2: Types of IVAD Related Infections16
Type

Location

Symptoms

Treatment

Blood stream

Systemic

Local

Insertion site or exit site

IV antibiotics and
remove device
Oral or IV antibiotics

Port Pocket

Subcutaneous pocket

Fever, hypotension,
purulent drainage
Edema, erythema,
induration, local
tenderness
Edema, erythema,
induration, purulent
drainage

Tunnel

Subcutaneous tunnel

Edema, erythema,
induration, purulent
drainage
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IV antibiotics, pack
pocket with
antibacterial gauze,
possible removal of
device
Catheter removal, IV
antibiotics, pack tunnel
with antibiotic gauze

Table 3: Types of Occlusions16
Occlusion
Drug precipitates

Fibrin deposits

Thrombus

Etiology

Outcome

Treatment

Drug crystallization in
catheter or tip from
infusion of incompatible
solutions or lack of
flushing
Sheath: fibrin adheres to
external catheter, can
extend full length of
catheter
Tail: fibrin located at
the catheter tip acting as
one-way valve
Deep vein: clot
formation at distal tip,
subclavian, axillary, or
brachiocephalic vein
Intraluminal: Fibrin or
clot within catheter

Partial or total
occlusion

Infuse solution to alter
pH, possible removal of
device

Partial or total
occlusion

Change position,
fibrinolytic therapy,
flush, IVAD removal

Partial occlusion

Change position,
fibrinolytic therapy,
flush
Anticoagulation or
fibrinolytic therapy,
possible IVAD removal

Mural: Fibrin forms
from a vessel wall
injury and binds to the
fibrin covering on the
catheter surface

Partial or total
occlusion

Total occlusion

Partial or total
occlusion
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Anticoagulation or
fibrinolytic therapy,
possible IVAD removal
Anticoagulation or
fibrinolytic therapy,
possible IVAD removal

LITERATURE REVIEW
Market Research
The Huber needle is the primary use for venous access for chemotherapy, dialysis, among
other treatments. The venous access market is defined by the use of catheters, ports, and
catheter securement devices.17 The venous access market will be our primary focus.
Revenue is valued at 6.5 billion dollars with a 1.2% growth. Most of the revenue comes
from the purchasing of venous access devices. Growth projections were made due to
increasing demographics requiring venous access, health care reform and product
innovation.17 Medicare increased physician visits but made cuts to reimbursing hospital
acquired infections. This has led to hospitals purchasing more expensive, antimicrobial
devices.17 There is a profit margin of 10.3%, coming from the reduction of inefficient
manufacturing plants, improving supply chains post COVID-19 pandemic, and low
market saturation of competitors. An important thing to note is the higher skilled labor
required to manufacture implantable devices, which somewhat limits profits. Alongside
manufacturing, many companies have in house sales teams to improve sales growth.17
Figure 5: Venous Access Market Breakdown
Other
10%

Implantable
Ports
25%

Peripherally
Inserted
Central
Catheters
50%

Central Venous
Catheters
15%
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As the population continues to age, there is an expanding market for venous access.17 In
addition to the aging demographic within the world, there is the ever-growing presence of
cancer. Chemotherapy is one of the leading treatments and is used in most cancers. There
is a large market totaling nearly 200 billion dollars for initial, continuing, and final
treatments for patients across all cancer types.18 This cost includes the cost of the drugs
and all the equipment. The IrisPort seeks to reduce the cost of chemotherapy by reducing
the required equipment to purchase for infusion procedures.
Table 4:Proportion of patients who receive chemotherapy in the U.S.9
Cancer Type

Stage 1

Stage 2

Stage 3

Stage 4

Bladder

50%

55%

61%

60%

Breast

17%*

62%

66%

Colon

9%*

66%

65%

Rectal

34%

Uterus

26%

79%*

70%

*Chemotherapy rates were combined within 2 stages
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78%

75%

73%

Table 5: Cost of Chemotherapy per Year18
Cancer Type
Bladder

Initial
1.5 billion

Continuing

Last

2.7 billion

1.6 billion

Breast

8.1 billion

10.6 billion

5.6 billion

Colorectal

8.6 billion

5.8 billion

6.3 billion

Uterus

1.5 billion

1.1 billion

1 billion

Dialysis makes up another part of the venous access and is worth 2.5 billion dollars.
Profit margins are smaller due to lower insurance reimbursement rates. This is due to
Medicare continually decreasing reimbursement rates over the past 5 years and the
increasing wages for manufacturing. Dialysis is done primarily in dialysis centers and
hospitals.19 Hospitals have the largest revenue and profit, 968.6 billion and 68.8 billion
dollars respectively. Hospitals have both inpatient and outpatient settings. Outpatient is
cheaper to maintain and is more cost-efficient.20 All three of the previously mentioned
markets are largely impacted by the reimbursement rates of insurance companies.
Medicare and other private insurance companies already have existing reimbursement
pathways to which this device would be eligible for. Medicare will typically reimburse
between $1,341.23-$2,770.97, with varying fees depending on site of procedure.21
Revenue can be limited by insurance companies, other companies, and other sources of
funding.
As mentioned previously, a large portion of patients report having a fear of needles.
Where most of all children and patients receiving chemotherapy are included in that
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proportion as seen in Table 6. This fear leads to 20% of people to avoid any and all
procedures.3 In addition to age, women are more likely to have a fear of needles when
compared to men.3 By eliminating a needle using a mechanical septum, the IrisPort hopes
to target patients with a fear of needles and increase patient compliance.
Table 6: Prevalence of "Needle-Phobia" in Cancer Patients3

When comparing the different markets, a few different companies were involved in all 3
markets. Baxter, BD, and Fresnius makes up the majority of dialysis and a larger portion
of the venous access market. The venous access market is more evenly spread out with
over 150 companies. Baxter is seeing a large revenue growth due to small business
acquisitions.17 These companies typically buy up smaller companies leading to a
monopoly.19 Hospital systems are continuing to get larger as they band together. As time
goes on the global market continues to grow, there has been an overall decrease in
American exports and an increase in imports. The majority is coming out of Ireland and
Mexico, and cost less overall. Our company has to be aware of key players undercutting
prices or attempting to buy out the company.17,19 The final thing that forces competition
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is the existence of group purchasing organizations. They can hinder growth as they have
a better ability to negotiate the prices of materials and medical devices.
User Needs
The design of the IVAD sought to eliminate needle punctures through the arm and allow
for a higher quality of living. From a higher risk of infection to the possibility of a restick, external catheters and IV administration through the arm can cause great
discomfort to the patient.22 With the IVAD, these risks are reduced. An IVAD provides
constant access to the bloodstream without the possibility of missing the vein through
needle access. The device can remain in the body for up to 5 years, and the time of
treatment is reduced. Although the IVAD has changed the way long-term patients receive
treatment, there are still user needs that remain.
The main cause of discomfort in patients receiving IV treatment is the needle. Regardless
of needle size, patients still feel some level of pain. In pediatric patients, a phobia of
needles may develop as they progress through their treatment path, leading them to
become less compliant.3 A needleless device could improve patient comfort and
compliance. In addition, infection rates caused by puncturing the skin with a needle could
decrease. Through antimicrobial materials and the absence of a needle, infection would
be less likely to develop. The size of the device may overall decrease with the reduction
of the septum size. Without a needle to puncture, the septa do not serve much purpose
and can possibly be eliminated.
Keeping in mind the nurses and physicians who will access the device, the port must be
easily accessible without a needle. An adapter similar to the tip of a standard 10 mL Luer
lock syringe will be connected to the device. This adapter will be designed as the male
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component with a swivel-skirt mechanism. The swivel-skirt mechanism allows for
connection without twisting the intravenous tubing. This simple, yet stable, connection
will allow for administration of fluids or withdrawal of blood. With easier access, the
time of treatment may be reduced, which would benefit both the patient and the
administrator.
Figure 6: Luer Lock Universal Adapter Predicate Device-Unengaged23

Figure 7:Luer Lock Universal Adapter Predicate Device- Engaged23

Device Features
With the user needs considered, the IVAD features become clear. The most radical
feature is a new way to access the bloodstream without the use of a needle. There is no
way to access the internal body without an opening in the skin. Therefore, the IVAD
must rest in the skin rather than under it. To allow for a continuous opening in the skin, it
will be imperative to keep the site clean and keep the area covered with an antimicrobial

13

covering. To prevent blood from leaking through the opening in the skin, a secure yet
stable opening system covering the reservoir is required. The opening must be collapsible
to avoid unnecessary increase in size of the device. The most prominent design is the iris
mechanism. The iris mechanism would consist of 5 leaflets that are fixed in between 2
circular discs. When turned clockwise, the leaflets retract between the 2 circular discs to
create a circular opening to the reservoir. This feature will allow for fluids to move
between the syringe and port reservoir by either injecting fluids into the reservoir or
withdrawing blood with the syringe. A connecting device (or a syringe adaptor) will need
to be attached to the iris mechanism. A male-end adaptor design for a standard syringe
female-end will allow the design to be universal.
In addition to the new opening feature of the device, the rest of the IVAD will resemble
its predecessors. A cylinder-shaped port reservoir with an opening for catheter tubing will
lie underneath the iris mechanism to serve as a gateway to the bloodstream. The reservoir
will need to manipulate turbulence of the bloodstream to create a vortex before exiting
the body through the syringe. The catheter will connect to the port reservoir and insert
into the intended vein.
The IVAD size needs to be minimized without making venous access with the syringe
difficult. Keeping an opening in the skin can cause discomfort but decreasing the size of
the IVAD may reduce the potential pain.
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Materials
Materials are considered biocompatible if they do not produce an immune response and
are not cytotoxic. Biocompatibility can be shown through in vivo and in vitro testing.24–26
These tests include cellular response and blood assays to quantify if a material causes an
immune response. As previously mentioned, IVADs consist of a septum, reservoir, and
catheter. While the shape of the reservoir may change depending on the manufacturer, the
materials rarely change. Typically, reservoirs and covers are made of either titanium or
polyurethane depending on patient’s needs and allergies.4 These materials have high
mechanical strength, are resistant to degradation are less expensive than other alloys.24–26
Raw materials would cost approximately $18-22/kilogram and $6/kilogram for titanium
and polyurethan, respectively.27 Polyurethane has been shown to have low monocyte
reactivity, high thermal and oxidative stability, and does not produce toxic leachable
materials.5,26 Titanium is also considered to be biocompatible as it has low electrical
conductivity allowing for an inert oxide layer to form spontaneously. It is this oxide layer
that resists corrosion over time, making it one of the preferred materials.25
Most septa are made with silicone and other self-healing polymers that allow for access
to the reservoir itself. Catheters are made with primarily silicone and polyurethane.5,24
Silicone is a synthetic polymer that has been used widely since 1940 due to its extensive
mechanical properties and high biocompatibility. Silicone has been proven to have high
thermal and chemical stability under a wide range of temperatures and conditions. Due to
its hydrophobic nature, silicone is considered to have high hemocompatibility.24 All of
these characteristics have been confirmed with in vitro and in vivo testing. Both silicone
and polyurethane offer different benefits. Silicone catheters have lower infection rates
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when compared with polyurethane catheters. However, silicone catheters have high rates
of mechanical failure in which they disconnect from the port. Both materials resist
surface degradation and allow for good blood flow.5 However, the majority of current
IVADs on the market use a polyurethane catheter (about 2:1).4 All the materials
mentioned are the most commonly used by current manufacturers.4
Infection Rates and Prevention
Infection is one of the several complications that can occur when implanting devices.
IVADs have been shown to best deliver long term venous access while limiting infection
rates. However, infection is a leading cause for replacing implanted ports. These
infections can be acquired by repeated, consecutive needle punctures and can be local or
systemic. Localized infections are confirmed by culturing exudate samples. Infected
portions of the port may be removed and replaced, or complete removal of the device
may be necessary. Systemic infections are seen if the infection has reached the blood
stream. The device should be removed, and patient be treated with antibiotics. In both
instances of infection, a replacement port should not be placed until the infections have
cleared.4
Infections detailed above can be mostly prevented with proper catheter maintenance and
hygiene. The Centers for Disease Control (CDC) created standardized guidelines for
proper catheter maintenance. Clinicians should wash their hands prior to palpating,
accessing, or dressing and IVAD. The skin at the site of the IVAD should be disinfected
with either chlorhexidine solution or 70% alcohol using a sterile swab. Cleansing of the
site should continue for 30 seconds with friction to kill as many harmful organisms as
possible. All IVADs should be flushed with 20 mL of normal saline before and after each
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access.28 The IVAD dressings should be replaced at least once a week, whenever the
dressings become dislodged, or if infection is suspected. In addition to proper hand
hygiene, IVADs should undergo catheter flushing. This is since biofilms tend to form on
the catheters. The biofilms can cause occlusions that can lead to a number of issues,
including infection (seen in Tables 1-3). IVADs can be flushed with either saline or
heparin. This should be done regularly to prevent occlusions and infection. Flushing is
essential especially when IVAD is not in use. 4
Sterilization Methods and Packaging
Infections can be largely prevented by sterilizing all medical devices and instruments.
There are several methods in which things can be sterilized. The majority of medical
devices and implants are sterilized in two ways, ethylene oxide (ETO) and radiation.29,30
ETO terminally sterilizes materials after they have been manufactured and packaged,
allowing for large quantities to be sterilized at one time. ETO is done by preconditioning
the load (materials) to get to a predefined temperature and humidity and air is removed to
create a vacuum. Steam may be added to maintain the desired humidity. The ETO is then
injected into the load, with nitrogen gas following to create top pressure and force the
ETO into the materials. After the proper amount of exposure time, the gases are removed,
and nitrogen is used to wash the materials. The final steps include ventilation and
aeration to ensure that no ETO remains. ETO is the preferred choice for medical devices
because it can sterilize most materials, including temperature and moisture sensitive
devices.29,30
The second most used form of sterilization is radiation, commonly gamma radiation.
Gamma radiation has short processing time, can penetrate multiple layers, and penetrate
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different types of packaging. Similar to ETO, gamma radiation sterilization is not
affected by humidity, temperature, and does not significantly heat the materials. The
radiation is emitted from an atom or molecule as the energy level drops. This method
uses the self-disintegration of cobalt-60. 29
The IrisPort will be packaged in standard plastic and paper containers that will be sealed.
Our product will likely use heat sealed sterilization pouches that cost between $0.38-0.51/
pouch.31 Packaging must be strong enough to resist punctures and tears.30 Following
packaging, the device will undergo either ETO or gamma radiation to be sterilized prior
to use. This packaging and sterilization will work to prophylactically prevent infections.
Table 7:Comparison of Sterilization Techniques29,30
Ethylene Oxide (ETO)

Radiation

Sterilant source

ETO gas

Gamma radiation

Uses

Single use devices, surgical
instruments, heat/moisture sensitive
devices

Some single use devices, heat sensitive,
radiation resistant plastics

Cost

>$45000

$150,000-$45000

Pros

Penetrate packaging, easy to use,
compatible with most medical
materials

Penetrate multilayer packaging, sort
processing time, not affected by humidity
levels

Cons

Toxic, aeration time to get rid of
residue, flammable, can contribute to
CO2 emissions

Expensive, can cause cracking in plastics
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RESEARCH PROPOSAL
Needs Statement and Value Proposition
The improved design for the issue at hand was based on an initial needs statement: “A
way to better administer long term fluid treatment using venous access devices to
eliminate patient discomfort and administration complications resulting from accessing
the device via a needle.” This statement was formulated based on the observation that
complications with intravenous access resulting from piercing or perforating the septum
by needles. By improving methods of long-term fluid treatment, a patient’s quality of life
can improve, nurses and physicians have less trouble administering treatment, and
engineers may have a new starting point for further improvement of the method of
treatment.
Potential Solutions
There are a few ways the needs statement can be solved. The first way is with a
collapsible needle. Before the needs statement was solidified, the focus was the sizing of
the needle. Many patients with an IVAD must use gauze underneath the wings of the port
to hold the needle in place during treatment. With a collapsible needle, the sizing of the
needle could be more compatible with the patient’s skin thickness. Each patient has a
different body type. While current non-coring needles come in a variety of sizes, it is
difficult for the needles to accommodate each skin thickness. With an adjustable needle,
patients would not be susceptible to multiple sticks, and hospitals would not have to
purchase different sized needles in bulk. However, while this solution would allow for a
comfortable fit of the port, the discomfort from needle insertion remains.
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The next focus was to eliminate the needle entirely from the IVAD access process. The
first method was to use magnets to access the reservoir. A magnet would lie between the
skin and push out of the way at the presence of a syringe. The magnet would securely
prevent backflow of blood out of the body and eliminates the needle. However, the
magnet would have to be strong enough to remain in place overtime, and it would be
difficult to comfortably access the reservoir. Additionally, magnets may interfere with
other devices such as pacemakers.
The second method was to use a venus box that twists to open.32 A base connects to 4
curved doors that, upon twisting the base, securely close or open the box. With this
design, the accessing process would flow smoothly by eliminating the needle and would
not require magnetic materials. However, the venus box does not ensure total closure, and
it would be possible for blood to leak.
Figure 8: Venus Box with Petals Open and Closed32
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Figure 9: Venus Box Partially Closed32

With the venus box still in mind, the final method was to use an iris mechanism that also
twists to open. There are 5 leaflets fixed in between 2 circular cases that retract when the
cases rotate in opposite directions. This method eliminates the needle, does not require
magnetic materials, and ensures a tighter closing. The mechanism of opening will be
discussed in the next section.
Implant Design
The design possibilities in the previous sections would theoretically solve the needs
statement, but the most stable design is the iris mechanism. The iris mechanism would be
the most comfortable method to access. With an adaptor for the syringe, the iris
mechanism would open with ease and close securely to prevent the leakage of blood. The
iris mechanism inner and outer case size would correspond with the Luer lock adaptor
dimensions. The dimensions for the prototype and proposed scaled down model can be
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found in Tables 8-10. For prototyping purposes, the device was scaled up 7.5 times
larger. The stages of the iris opening can be seen in the images below.
Table 8: Scaled Up Prototype IrisPort Dimensions
Part
Outer case
Inner case
Leaflet
Internal
Reservoir

Inner Diameter
37.04 mm
37.04 mm
-

Outer Diameter Height
74.37 mm
6.29 mm
70.13 mm
2.18 mm
2.45 mm

90 mm

-

Length
23.27 mm

37.5 mm

-

Table 9: Scaled Down IrisPort Prototype Dimensions
Part
Outer case
Inner case
Leaflet
Internal
Reservoir

Inner Diameter
2.1 mm
2.1 mm
-

Outer Diameter Height
4.22 mm
0.36 mm
3.98 mm
0.12 mm
0.14 mm

12 mm

-

Length
1.32 mm

5 mm

-

Table 10: Reservoir Casing Dimensions
Protype Type Size
Large
Scaled Down

Equatorial axis (a)
54.5 mm
7.26 mm

Figure 10: Spheroid Axes and Dimensions Diagram33

22

Polar axis (c)
23.8 mm
3.17 mm

Figure 11: Closed Iris on Z and -Z Axes of Scaled Up Prototype
A

B

Figure 11-A: Closed iris on the Z axis. Figure 11-B: On the right is the closed iris on the -Z axis.

Figure 12: Partially Open Iris on Z and -Z Axes of Scaled Up Prototype
A

B

Figure 12-A: Partially open iris on the Z axis. Figure 12-B: Partially open iris on the -Z axis.
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Figure 13: Completely Open Iris on Z and -Z Axes of Scaled Up Prototype
A

B

Figure 13-A: Completely open iris on the Z axis. Figure 13-B: Completely open iris on the -Z axis.

Figure 14: Port and Iris Side View of Scaled Up Prototype

The photo above is the side view of the iris mechanism completely open.
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Additionally, the port reservoir is modeled after existing port reservoirs that have been
optimized for fluid flow. The round design of the reservoir will promote a vortex that
ensures fluid flow reaches all areas of the reservoir. The catheter opening lies tangentially
within the wall of the reservoir to further allow a consistent flow of blood or fluids. The
opening of the reservoir will match the outer diameter of the inner case of the iris
mechanism at 2.2 mm.
Figure 15: Reservoir Z and -Z View of Scaled Up Prototype
A

B

Figure 15-A: Port reservoir on the Z axis. Figure 15-B: Port reservoir on the -Z axis.
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Figure 16: Reservoir Side Views of Scaled Up Prototype
A

B

Figure 16-A: Side view of the reservoir. Figure 16-B: Elevated side view of the reservoir.

Figure 17: Leaflet Design of Scaled Up Prototype

A

B

Figure 17-A: Leaflet on the Z axis. Figure 17-B: Elevated side view of the leaflet.

26

Proposed Surgical Protocol
The following protocol is adapted from existing surgical procedures that have been
approved by the FDA.34 Prior to the procedure, health care providers must have a
comprehensive medical history including previous procedures and allergies. Patients also
should go through routine blood work to confirm that their platelet count is <50,000 and
prothrombin values >18. Cancer patients should discontinue all chemotherapy at least 2
weeks prior to the procedure.
Step 1: Sterilize the chest and neck region with chlorhexidine and drape the patient so
that the face is covered. All individuals involved in the procedure must have proper
personal protective equipment (PPE) including surgical gowns, gloves, masks, and eye
protection. The patient should be given prophylactic antibiotics. Per the Society of
Interventional Radiology (SIR) Standards of Practice Committee 1 gram of intravenous
cefazolin or an equivalent antibiotic.
Step 2: Using an ultrasound, puncture the internal jugular vein to gain access to the right
atrium. An angled access point will eliminate entry scar. The needle sheath is advanced
into the vena cava and the port catheter is inserted.
Step 3: Administer subcutaneous local anesthesia and make an incision for the port
pocket. Incisions should be at least 3 cm from the catheter entry. A distance of 5 cm is
often preferred as it decreases the chance of bacterial migration from the port pocket into
the blood stream. The port should be between 5 and 20 mm beneath the skin. Ideal
placement of the port would be over an anterior rib to provide support for future
palpation and access.
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Step 4: Following the creation of the port pocket and tunnel, the catheter is pulled
through the IVAD and through the tunnel. The catheter tip should be approximately 2
vertebral bodies below the carina. To prevent movement of the port, suture the port to the
fascia with a resorbable 4-0 polyglactin suture.
Step 5: Prior to closure, the port function must be verified. This can be done by aspiration
and injection using a noncoring needle, following with a 100 u/cc heparin. Once function
has been verified, the incision may be closed using 2 to 3 interrupted deep sutures and a
running subcuticular resorbable suture (ideally 4-0 polyglactin).
Step 6: Patients must be observed for at least one hour after the procedure to allow for the
anesthesia to wear off and ensure there is no pain or bleeding at the surgical site.
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Validation
To proceed with the proposed IVAD device, there will be several tests that need to be
performed. The first test will be mechanical testing. The strength of the device features
will need to be considered because the device will undergo minor stress during accessing.
The IVAD device prototype was 3D printed using ABS plastic filament from a Stratasys
printer. The prototype was scaled up to visualize the iris mechanism. The iris mechanism
open and closed with ease. However, the pegs that hold the leaflets onto the top circular
case broke when too much force was applied. This signals that the pegs, regardless of
material, may need to be adjusted to prevent stress. No other features of the prototype
indicated failure upon mechanical stress.
The next step will be to test the flow within the port reservoir. The round design of the
reservoir is to ensure all surfaces of the interior are reachable by the fluid. The flow of
fluid resulting from the tangent opening in the reservoir will reduce buildup of materials
and potentially reduce infection. The catheter opening is set at a tangent angle to promote
a circular flow of fluids. However, there have been no tests to confirm if the current
design will accomplish these goals. Testing must be conducted before the prototype may
proceed, including functional tests to ensure high patient compliance. The device should
be able to withstand the pulling and movement of the cannulas and medical tubing.
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FUTURE WORKS
The next prototype will be made from titanium and polyurethane. Each device will cost
between $225-275 and $50 to 3D print for titanium and polyurethane respectively. They
will be 3D printed as it is much more cost effective than injection molding for smaller
quantities. Future tests include mechanical stress testing, biocompatibility assays, and
corrosion testing. Our device would need to undergo mechanical fatigue tests to confirm
that the device can handle the repeated forces placed on it for port access.35 Fatigue
testing is carried out cyclically (repeatedly loaded) until failure. Previous studies have
shown that grade 2 titanium can withstand up to 109 MPa in stress and up to 350 MPa in
loading. Our device should be able to withstand similar amounts of stress and forces. In
addition to fatigue testing, the IrisPort should undergo torsion testing, both axial and
functional testing. Torsion testing is done by applying a rotational motion, either with or
without compression forces.36 Pure grade 2 titanium has a breaking angle of 253° and
shear stress of around 260 MPa in shear stress. 37 Functional testing must also be
conducted to verity that the IrisPort can handle repeated twisting of the syringe adapter
piece. 36 Finally, there are luer lock tests that can be done to ensure the lock does not leak
(connection integrity testing) and there is an ease of connection. The leaking tests would
consist of 27.5 N of top loaded axial force and simultaneous 0.12 N*m of torque for
metals and 20 N and 0.08 N*m for plastics, respectively. These tests are described in the
international standard ISO 594 ½. 38,39 As the iris mechanical septum is novel, it must be
tested separately and attached to the port to ensure limited mechanical failure.40
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Biocompatibility assays will include a hemocompatibility test following the ISO
standard 10993-4.41 Hemocompatibility testing is required because the IrisPort system
will consistently come in contact with blood. To be considered hemocompatible, the
device must not cause any significant reactions including: thrombosis, hemolysis,
platelet, leukocyte and complement activation or any other blood-related adverse
event.40,41 Hemocompatibility tests include coagulation (clotting caused by thrombin
confirmed with ELISA), hemolysis (quantified by increased plasma hemoglobin levels
caused by damage), and a simulated circulatory system via a Chandler Loop or parallelplate chambers.41,42 Chandler Loops are an ex vivo testing that allows blood to flow
through tubing, much like in blood vessels, from a pump that pushes the blood through
tubing. A Chandler Loop can be linked to the catheter of the IrisPort to confirm that
blood can flow smoothly and without clotting. In addition to monitoring flow, Chandler
loops can monitor anti-inflammatory properties of the device.42 In addition to
hemocompatibility testing it is essential to go through pyrogenicity testing to determine if
the device is non-pyrogenic or meet pyrogen limit specifications.40 The limits set forth by
the FDA are 0. .5 EU/mL or 20 EU/device for products that directly or indirectly contact
the cardiovascular system and lymphatic system.43
The last in vivo testing includes corrosion testing. Our device will focus on cyclic
polarization testing. Cyclic polarization tests for the pitting and crevice corrosion
resistance.44,45 The CPDP measurements should follow the ASTM standards (F2129, G5,
G59, G61) and will likely be done in an external lab due to the difficult nature of
interpreting the results.44,45
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Once sufficient initial testing has been done, we would look to do an animal study, in
which our product specific port maintenance routine can be established. Many implanted
port systems are evaluated using pigs.46 Swine are commonly used for diagnosis,
treatment, and prevention of diseases in humans.46 Due to their similar cardiovascular
systems, researchers can induce a number of human diseases- atherosclerosis, myocardial
infarction, etc. 46 They also have similar wound-healing pathways, which will allow us to
see how viable the IrisPort is when implanted flush with the skin. Intracutaneous testing
can be done to ensure that the device does not cause excess skin irritation.40 Additionally,
isolation of PBMC, monocytes, granulocytes, cytokine quantification can be done via
ELISA testing to confirm biocompatibility. The initial maintenance would follow current
protocols and then be adapted to ensure the mechanical septum remains clean and
occlusion free. A more detailed pig study will be established following all in vitro and ex
vivo testing. All of the previously mentioned testing must ensure that it meets the
requirements of the ISO 10993-1:2009 recommended endpoints for cytotoxicity,
sterilization, implantation, and hemocompatibility.40
Biomedical devices are developed to help the patient. Sales, while vital to the success of
the device, are secondary. The IrisPort began with the user need to ease discomfort
during the venous access process. As is apparent, the initial idea of the design to the first
prototype can radically change. Upon successful testing, the IrisPort is expected to
succeed in the medical and market fields.
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